Skip to main content
SpringerLink
Log in

Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics and development of antinuclear antibodies (ANAs) during procainamide (PA) therapy were studied in 35 patients with ventricular arrhythmias. Sixteen of the subjects were rapid and 19 were slow acetylators. Twenty-six of them (13 rapid and 13 slow acetylators) received PA therapy (2.4 g sustained-release PA·HCl daily in three doses) for at least 16 weeks. On maintenance therapy, rapid acetylators had insignificantly lower serum PA concentrations and slightly higher N-acetylprocainamide (NAPA) concentrations than slow acetylators. The unchanged PA fraction (PA/PA + NAPA) in the rapid acetylators was somewhat lower than in the slow acetylators. Rapid acetylators excreted more NAPA in urine than did slow acetylators (p<0.05), whereas the difference in PA excretion was not significant. More than 80% of the given drug was excreted as PA and NAPA. Spontaneous or exercise-induced arrhythmias were recorded in 6 rapid and 8 slow acetylators. ANAs (titre at least 20) appeared in 6 rapid and 8 slow acetylators. The mean time until ANA development in rapid acetylators was only marginally longer than in slow acetylators. The results suggest that acetylation phenotyping is not of great significance in predicting the development of ANAs during PA therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Atkinson AJ Jr, Lee W-K, Quinn ML, Kushner W, Nevin MJ, Strong JM (1977) Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions. Clin Pharmacol Ther 21: 575–587

    Google Scholar 

  • Atkinson AJ Jr, Strong JM (1977) Effect of active drug metabolites on plasma level-response correlations. J Pharmacokin et Biopharm 5: 95–109

    Google Scholar 

  • Birkhead J, Evans T, Mumford P, Martinez E, Jewitt D (1976) Sustained release procainamide in patients with myocardial infarction. Br Heart J 38: 77–80

    Google Scholar 

  • Bratton AC, Marshall EK Jr (1939) A new coupling component for sulfanilamide determination. J Biol Chem 128: 537–550

    Google Scholar 

  • Campbell W, Tilston WJ, Lawson DH, Hutton I, Lawrie TDV (1976) Acetylator phenotype and the clinical pharmacology of slow-release procainamide. Br J Clin Pharmacol 3: 1023–1026

    Google Scholar 

  • Davies DM, Beedie MA, Rawlins MD (1975) Antinuclear antibodies during procainamide treatment and drug acetylation. Br Med J 3: 682–683

    Google Scholar 

  • Frislid K, Berg M, Hansteen V, Lunde PKM (1976) Comparison of the acetylation of procainamide and sulfadimidine in man. Eur J Clin Pharmacol 9: 433–438

    Google Scholar 

  • Gibsona TP, Matusik J, Matusik E, Nelson HA, Wilkinson J, Briggs WA (1975) Acetylation of procainamide in man and its relation to isonicotinic acid hydrazide acetylation phenotype. Clin Pharmacol Ther 17: 395–399

    Google Scholar 

  • Graffner C, Johnsson G, Sjögren J (1975) Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. Clin Pharmacol Ther 17: 414–423

    Google Scholar 

  • Henningsen NC, Cederberg A, Hanson A, Johannson BW (1975) Effects of long-term treatment with procaine amide. Acta Med Scand 198: 475–482

    Google Scholar 

  • Karlsson E (1975) Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels. Br Heart J 37: 731–740

    Google Scholar 

  • Karlsson E (1978) Clinical pharmacokinetics of procainamide. Clin Pharmacokinet 3: 97–107

    Google Scholar 

  • Karlsson E, Molin L (1975) Polymorphic acetylation of procaine amide in healthy subjects. Acta Med Scand 197: 299–302

    Google Scholar 

  • Karlsson E, Molin L, Norlander B, Sjöqvist F (1974) Acetylation of procaine amide in man studied with a new gas chromatographic method. Br J Clin Pharmacol 1: 467–475

    Google Scholar 

  • Kluger J, Drayer D, Reidenberg M, Ellis G, Lloyd V, Tyber T, Hayes J (1980) The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias. Am J Cardiol 45: 1250–1257

    Google Scholar 

  • Koch-Weser J (1977) Serum procainamide levels as therapeutic guides. Clin Pharmacokinet 2: 389–402

    Google Scholar 

  • Koch-Weser J, Klein SW (1979) Procainamide dosage schedules, plasma concentrations and clinical effects. J Am Med Assoc 215: 1454–1460

    Google Scholar 

  • Koch-Weser J, Klein SW, Foo-Canto LL, Kastor JA, Descantis RW (1969) Antiarrhythmic prophylaxis with procaine amide in acute myocardial infarction. N Engl J Med 281: 1253–1260

    Google Scholar 

  • Lee W-K, Strong JM, Kehoe RF, Dutcher JS, Atkinson AJ Jr (1976) Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions. Clin Pharmacol Ther 19: 508–514

    Google Scholar 

  • Lertora JJL, Atkinson AJ Jr, Kushner W, Nevin MJ, Lee W-K, Jones C, Schmid FR (1979) Long-term antiarrhythmic therapy with N-acetylprocainamide. Clin Pharmacol Ther 25: 273–282

    Google Scholar 

  • Lunde PKM, Frislid K, Hansteen V (1977) Disease and acetylation polymorphism. Clin Pharmacokinet 2: 182–197

    Google Scholar 

  • Matusik E, Gibson TP (1975) Fluorometric assay for N-acetylprocainamide. Clin Chem 21: 1899–1902

    Google Scholar 

  • Reidenberg MM, Drayer DE, Levy M, Warner H (1975) Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 17: 722–730

    Google Scholar 

  • Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, Woosley RL (1980) Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: Comparison with procainamide. Am J Cardiol 46: 463–468

    Google Scholar 

  • Ruosteenoja R, Torsti P, Sothmann A (1973) Experiences on a sustained-release procainamide preparation. Curr Ther Res 15: 707–712

    Google Scholar 

  • Schröder P, Klitgaard NA, Simonsen E (1979) Significance of the acetylation phenotype and the therapeutic effect of procainamide. Eur J Clin Pharmacol 15: 63–68

    Google Scholar 

  • Sonnhag C, Karlsson E (1979) Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide. Eur J Clin Pharmacol 15: 311–317

    Google Scholar 

  • Sonnhag C, Karlsson E, Hed J (1979) Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide. Acta Med Scand 206: 245–251

    Google Scholar 

  • Stec PG, Atkinson AJ Jr, Nevin MJ, Thenot J-P, Ruo TI, Gibson TP, Ivanovich P, del Greco F (1979) N-acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. Clin Pharmacol Ther 26: 618–628

    Google Scholar 

  • Strong JM, Dutcher JS, Lee W-K, Atkinson AJ Jr (1975a) Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Clin Pharmacol Ther 18: 613–622

    Google Scholar 

  • Strong JM, Dutcher JS, Lee W-K, Atkinson AJ Jr (1975b) Pharmacokinetics in man of the N-acetylated metabolite of procainamide. J Pharmacokinet Biopharm 3: 223–235

    Google Scholar 

  • Tilstone WJ, Lawson DH, Campbell W, Hutton I, Lawrie TDV (1978) The pharmacokinetics of slow-release procainamide. Eur J Clin Pharmacol 14: 261–265

    Google Scholar 

  • Wierzchowiecki M, Michalowska D, Lowicki Z, Ochotny R, Grześkowiak A, Tomaszkiewicz T (1980) Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects. Int J Clin Pharmacol Ther Toxicol 18: 272–276

    Google Scholar 

  • Wilson JD (1980) Antinuclear antibodies and cardiovascular drugs. Drugs 19: 292–305

    Google Scholar 

  • Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA (1978) Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 21: 1157–1159

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, University of Tampere, Tampere University Central Hospital, and the Research Laboratories of Star Ltd., Tampere, Finland

    P. Ylitalo, R. Ruosteenoja, O. Leskinen & T. Metsä-Ketelä

  2. Department of Pharmacology and Toxicology, University of Kuopio, P.O. Box 138, SF-70101, Kuopio 10, Finland

    P. Ylitalo

Authors
  1. P. Ylitalo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Ruosteenoja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. Leskinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Metsä-Ketelä
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ylitalo, P., Ruosteenoja, R., Leskinen, O. et al. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide. Eur J Clin Pharmacol 25, 791–795 (1983). https://doi.org/10.1007/BF00542522

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00542522

Key words

Search

Navigation